A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled "Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD" has been ...

Explore 2025's groundbreaking scientific discoveries: the MoM-z14 galaxy, personalised CRISPR therapy, regenerative medicine, ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments ahead of Christmas, on December 23, ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, ...

Anyone who has grown up eating freshwater fish knows the drill. You eat slowly. You chew twice. You stop mid-bite because ...